Alizyme plc

ALIZYME TO PRESENT AT THE 2008 PIPER JAFFRAY EUROPE CONFERENCE

Cambridge UK, 20 June 2008: Alizyme plc (LSE: AZM) announces that Tim McCarthy, Chief Executive Officer, will be presenting at the 2008 Piper Jaffray Europe Conference on Tuesday, June 24, 2008 at 3.00pm (BST).

This presentation will be available via live webcast on the Company's website at www.alizyme.com. A replay of the webcast will also be available after the conference.

For the live webcast, please ensure that you are logged on approximately10 minutes before the start of the presentation at 2.50pm (BST).

For further information, please contact:

Further information on Alizyme can be found on the Company's website: www.alizyme.com

EDITOR'S NOTES

Alizyme is a speciality biopharmaceutical development company, based in Cambridge, UK, targeting the treatment and management of gastrointestinal disorders, obesity and diabetes. It has a portfolio of products which include: cetilistat (prepared for commencement of Phase III development for the treatment of obesity and diabetes), COLAL-PRED® (in Phase III development in Europe for the treatment of acute ulcerative colitis) and ATL-104 (successfully completed a Phase IIa trial for the treatment of mucositis). 

• News Channel